iShares Biotechnology ETF
IBB
IBB
414 hedge funds and large institutions have $3.86B invested in iShares Biotechnology ETF in 2016 Q1 according to their latest regulatory filings, with 67 funds opening new positions, 130 increasing their positions, 143 reducing their positions, and 75 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
414
Holders Change
-17
Holders Change %
-3.94%
% of All Funds
11.05%
Holding in Top 10
21
Holding in Top 10 Change
-11
Holding in Top 10 Change %
-34.38%
% of All Funds
0.56%
New
67
Increased
130
Reduced
143
Closed
75
Calls
$608M
Puts
$901M
Net Calls
-$292M
Net Calls Change
+$278M
Top Buyers
| 1 |
1
Citigroup
New York
|
$441M |
| 2 |
2
Bank of America
Charlotte,
North Carolina
|
$593M |
| 3 |
3
Jane Street
New York
|
$70.4M |
| 4 |
4
Two Sigma Advisers
New York
|
$51.4M |
| 5 |
5
Alyeska Investment Group
Chicago,
Illinois
|
$49.6M |
Top Sellers
| 1 |
1
BNP Paribas Financial Markets
Paris,
France
|
$212M |
| 2 |
2
JPMorgan Chase & Co
New York
|
$9.72M |
| 3 |
3
Goldman Sachs
New York
|
$573M |
| 4 |
4
Morgan Stanley
New York
|
$371M |
| 5 |
5
Wells Fargo
San Francisco,
California
|
$32.9M |
